BACKGROUND: There is considerable interest in the expression of cancer testis (CT) antigens in human cancers, because they may serve as the basis for diagnostic tests or an immunologic approach to therapy, or as prognostic markers. METHODS: On this basis, we evaluated by semiquantitative reverse-transcriptase polymerase chain reaction (RT-PCR) the expression of genes that code for tumor antigens (melanoma antigen-1 [MAGE-1], MAGE-4, MAGE-10, MAGE-12, B melanoma antigen, CTL-recognized antigen melanoma antigen (CT antigen 2) [LAGE], New York esophageal squamous cell carcinoma antigen (CT antigen 1) [NYESO-1], and preferentially expressed antigen of melanoma [PRAME]) in surgical samples of the tumors, margins, and lymph nodes (when present) from patients with a diagnosis of head and neck carcinoma. The study was conducted on 33 patients (31 men and two women), aged 31 to 94 years (mean, 56 years), with squamous cell carcinomas located in the mouth (15 cases), larynx (14 cases), and pharynx (four cases). RESULTS: The findings were compared with the clinical course and laboratory data. Expression of at least one antigen was observed in 66.6% of cases, with different rates of expression according to tumor staging (100% of T4, 57% of T3, 50% of T1 and T2) and smoking habit. There was a significantly higher expression of multiple genes (two or more) in tumors in advanced stages. CONCLUSIONS: We conclude that the tumor-specific antigen genes are expressed in variable frequencies and intensities in the primary lesions of head and neck squamous cell carcinomas and in their metastases, with expression of the PRAME gene being always present in the metastastatic lymph nodes. In primary lesions, gene expression correlated with smoking habit and with advanced tumors with a higher malignant potential, with the frequent expression of two or more of these genes. Copyright 2006 Wiley Periodicals, Inc.
BACKGROUND: There is considerable interest in the expression of cancer testis (CT) antigens in humancancers, because they may serve as the basis for diagnostic tests or an immunologic approach to therapy, or as prognostic markers. METHODS: On this basis, we evaluated by semiquantitative reverse-transcriptase polymerase chain reaction (RT-PCR) the expression of genes that code for tumor antigens (melanoma antigen-1 [MAGE-1], MAGE-4, MAGE-10, MAGE-12, B melanoma antigen, CTL-recognized antigen melanoma antigen (CT antigen 2) [LAGE], New York esophageal squamous cell carcinoma antigen (CT antigen 1) [NYESO-1], and preferentially expressed antigen of melanoma [PRAME]) in surgical samples of the tumors, margins, and lymph nodes (when present) from patients with a diagnosis of head and neck carcinoma. The study was conducted on 33 patients (31 men and two women), aged 31 to 94 years (mean, 56 years), with squamous cell carcinomas located in the mouth (15 cases), larynx (14 cases), and pharynx (four cases). RESULTS: The findings were compared with the clinical course and laboratory data. Expression of at least one antigen was observed in 66.6% of cases, with different rates of expression according to tumor staging (100% of T4, 57% of T3, 50% of T1 and T2) and smoking habit. There was a significantly higher expression of multiple genes (two or more) in tumors in advanced stages. CONCLUSIONS: We conclude that the tumor-specific antigen genes are expressed in variable frequencies and intensities in the primary lesions of head and neck squamous cell carcinomas and in their metastases, with expression of the PRAME gene being always present in the metastastatic lymph nodes. In primary lesions, gene expression correlated with smoking habit and with advanced tumors with a higher malignant potential, with the frequent expression of two or more of these genes. Copyright 2006 Wiley Periodicals, Inc.
Authors: Till J Meyer; Stefan Hartmann; Gisela Wohlleben; Muna Brisam; Axel Seher; Alexander C Kübler; Bülent Polat; Urs D A Müller-Richter Journal: Mol Clin Oncol Date: 2018-01-19
Authors: Sang Tae Noh; Hyoung Shin Lee; Soo Jin Lim; Sung Won Kim; Hee Kyung Chang; Junghwan Oh; Chang-Ho Jeon; Jong Wook Park; Kang Dae Lee Journal: Int J Clin Oncol Date: 2016-05-26 Impact factor: 3.402
Authors: Frances Wadelin; Joel Fulton; Paul A McEwan; Keith A Spriggs; Jonas Emsley; David M Heery Journal: Mol Cancer Date: 2010-08-27 Impact factor: 27.401
Authors: Urs D A Müller-Richter; Albert Dowejko; Oliver Driemel; Tobias Reuther; Torsten E Reichert; Alexander C Kübler Journal: Oncol Lett Date: 2010-01-01 Impact factor: 2.967
Authors: Urs D A Müller-Richter; Albert Dowejko; Silvia Peters; Stephan Rauthe; Tobias Reuther; Stefan Gattenlöhner; Torsten E Reichert; Oliver Driemel; Alexander C Kübler Journal: Clin Oral Investig Date: 2009-06-02 Impact factor: 3.573
Authors: Miroslaw J Szczepanski; Albert B DeLeo; Michał Łuczak; Marta Molinska-Glura; Jan Misiak; Bronislawa Szarzynska; Grzegorz Dworacki; Mariola Zagor; Natalia Rozwadowska; Maciej Kurpisz; Antoni Krzeski; Aleksandra Kruk-Zagajewska; Tomasz Kopec; Jacek Banaszewski; Theresa L Whiteside Journal: Oral Oncol Date: 2012-09-01 Impact factor: 5.337